Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

How to buy Incyte Corporation stock | $85.39

Own Incyte Corporation stock in just a few minutes.

Posted

Fact checked

Incyte Corporation is a biotechnology business based in the US. Incyte Corporation shares (INCY) are listed on the NASDAQ and all prices are listed in US Dollars. Incyte Corporation employs 1,456 staff and has a trailing 12-month revenue of around USD$2.4 billion.

How to buy shares in Incyte Corporation

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Incyte Corporation Find the stock by name or ticker symbol: INCY. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Incyte Corporation reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$85.39, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Incyte Corporation, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Incyte Corporation. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Incyte Corporation's share price?

Since the stock market crash in March caused by coronavirus, Incyte Corporation's share price has had significant positive movement.

Its last market close was USD$85.39, which is 5.27% up on its pre-crash value of USD$80.89 and 36.67% up on the lowest point reached during the March crash when the shares fell as low as USD$62.48.

If you had bought USD$1,000 worth of Incyte Corporation shares at the start of February 2020, those shares would have been worth USD$866.20 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,170.70.

Incyte Corporation share price

Use our graph to track the performance of INCY stocks over time.

Incyte Corporation shares at a glance

Information last updated 2020-09-21.
Latest market closeUSD$85.39
52-week rangeUSD$62.48 - USD$110.37
50-day moving average USD$93.935
200-day moving average USD$93.4336
Wall St. target priceUSD$106.2
PE ratio 47.639
Dividend yield N/A (0%)
Earnings per share (TTM) USD$1.871

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Available asset types Stock trade fee Option trade fee Annual fee
Vanguard
Stocks,Mutual funds,ETFs,Forex
$0
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
Stocks,Options,ETFs,Cryptocurrency
$0
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks,Bonds,Options,Mutual funds,Index funds,ETFs,Forex,Futures,Cash
$0
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
Stocks,Options,ETFs,Futures
$0
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
M1 Finance
M1 Finance
Stocks,ETFs
$0
$0
0%
A robo-advisor that puts you in the driver’s seat with fully-customizable portfolios.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Incyte Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Incyte Corporation price performance over time

Historical closes compared with the last close of $85.39

1 week (2020-09-11) N/A
1 month (2020-08-18) N/A
3 months (2020-06-22) -21.61%
6 months (2020-03-18) N/A
1 year (2019-09-18) N/A
2 years (2018-09-18) N/A
3 years (2017-09-18) N/A
5 years (2015-09-18) N/A

Is Incyte Corporation under- or over-valued?

Valuing Incyte Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Incyte Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Incyte Corporation's P/E ratio

Incyte Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 48x. In other words, Incyte Corporation shares trade at around 48x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Incyte Corporation's PEG ratio

Incyte Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7842. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Incyte Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Incyte Corporation's EBITDA

Incyte Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$467 million.

The EBITDA is a measure of a Incyte Corporation's overall financial performance and is widely used to measure a its profitability.

Incyte Corporation financials

Revenue TTM USD$2.4 billion
Gross profit TTM USD$890.4 million
Return on assets TTM -3.77%
Return on equity TTM -8.32%
Profit margin -8%
Book value $10.752
Market capitalisation USD$19.4 billion

TTM: trailing 12 months

Shorting Incyte Corporation shares

There are currently 5.3 million Incyte Corporation shares held short by investors – that's known as Incyte Corporation's "short interest". This figure is 2.9% down from 5.4 million last month.

There are a few different ways that this level of interest in shorting Incyte Corporation shares can be evaluated.

Incyte Corporation's "short interest ratio" (SIR)

Incyte Corporation's "short interest ratio" (SIR) is the quantity of Incyte Corporation shares currently shorted divided by the average quantity of Incyte Corporation shares traded daily (recently around 1.1 million). Incyte Corporation's SIR currently stands at 4.8. In other words for every 100,000 Incyte Corporation shares traded daily on the market, roughly 4800 shares are currently held short.

However Incyte Corporation's short interest can also be evaluated against the total number of Incyte Corporation shares, or, against the total number of tradable Incyte Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Incyte Corporation's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Incyte Corporation shares in existence, roughly 20 shares are currently held short) or 0.0285% of the tradable shares (for every 100,000 tradable Incyte Corporation shares, roughly 29 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Incyte Corporation.

Find out more about how you can short Incyte Corporation stock.

Incyte Corporation's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Incyte Corporation.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Incyte Corporation's total ESG risk score

Total ESG risk: 34.23

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Incyte Corporation's overall score of 34.23 (as at 08/01/2020) is nothing to write home about – landing it in it in the 55th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Incyte Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Incyte Corporation's environmental score

Environmental score: 6.63/100

Incyte Corporation's environmental score of 6.63 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Incyte Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Incyte Corporation's social score

Social score: 27.6/100

Incyte Corporation's social score of 27.6 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Incyte Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Incyte Corporation's governance score

Governance score: 10.99/100

Incyte Corporation's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Incyte Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Incyte Corporation's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Incyte Corporation scored a 1 out of 5 for controversy – the highest score possible, reflecting that Incyte Corporation has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Incyte Corporation was last rated for ESG on: 2020-08-01.

Total ESG score 34.23
Total ESG percentile 54.7
Environmental score 6.63
Environmental score percentile 8
Social score 27.6
Social score percentile 8
Governance score 10.99
Governance score percentile 8
Level of controversy 1

Incyte Corporation share dividends

We're not expecting Incyte Corporation to pay a dividend over the next 12 months.

Have Incyte Corporation's shares ever split?

Incyte Corporation's shares were split on a 2:1 basis on 1 September 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Incyte Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Incyte Corporation shares which in turn could have impacted Incyte Corporation's share price.

Incyte Corporation share price volatility

Over the last 12 months, Incyte Corporation's shares have ranged in value from as little as $62.48 up to $110.37. A popular way to gauge a stock's volatility is its "beta".

INCY.US volatility(beta: 1.06)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Incyte Corporation's is 1.0641. This would suggest that Incyte Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Incyte Corporation overview

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; and Zai Lab Limited. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site